Panax notoginseng improves the sensitivity of non-small cell lung cancer to cisplatin by inhibiting Akt signaling
Cancer Biomarkers · 2025
DOI: 10.1177/18758592241303377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, 2025. Verfasst von Lizhen Pan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Cisplatin, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins c-akt, Panax notoginseng. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, Zhejiang Chinese medical university Special research projects of affiliated hospitals.
Abstract (Originalsprache)
Background
Cisplatin (DDP) resistance is a major challenge in the management of non-small cell lung cancer (NSCLC). Panax notoginseng has anticancer effects on a variety of solid tumors, but data on NSCLC and DDP resistance are lacking.
Objective
To investigate the effect of Panax notoginseng on DDP resistance in NSCLC in vitro and in vivo and explore the mechanisms involved.
Methods
A 1 g/mL Panax notoginseng extract was prepared to treat the A549 and DDP-resistant A549/DDP cell lines. Cell proliferation was assessed using the CCK-8 assay, and apoptosis was measured via Annexin V-FITC/PI staining and flow cytometry. Glucose uptake, ATP production, and lactate levels were evaluated. Protein levels of p-AKT, GLUT1, HKII, and cleaved-caspase-3 were analyzed by Western blot. IGF1 was used to activate the Akt pathway. In vivo, A549/DDP cells were inoculated into nude mice to establish subcutaneous tumors, and tumor growth and apoptosis were assessed.
Results
Panax notoginseng inhibited A549/DDP cell proliferation, enhanced DDP-induced apoptosis, and reduced glucose uptake, ATP, and lactate levels (all p < 0.05). Combined treatment decreased p-AKT, GLUT1, and HKII expression while increasing cleaved-caspase-3( p < 0.05). IGF1 reversed these effects, indicating Akt pathway involvement ( p < 0.05). In vivo, Panax notoginseng and DDP significantly suppressed tumor growth and increased apoptosis in tumors, confirming enhanced chemosensitivity ( p < 0.05).
Conclusion
Panax notoginseng can improve the sensitivity of A549/DDP cells to DDP by inhibiting the effects of TRIM46 and Akt signaling pathways on glycolysis in vivo and in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nursing, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, China.
- Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, China.
- Department of Nursing, Central Health Center of Zeya Town, Wenzhou, China.
- Department of Encephalopathy, Rui'an Traditional Chinese Medicine Hospital, Wenzhou, China.
- Department of Internal Medicine, Yueqing Traditional Chinese Medicine Hospital, Yueqing, China.
- Oncology Department, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, China.
Förderung
- Natural Science Foundation of Zhejiang Province
- Zhejiang Chinese medical university Special research projects of affiliated hospitals
Zitieren
APA
Pan, L., Zhang, D., Shao, Q., Cheng, M., Liao, Z., Yu, L., Wang, Y., Jia, P., & Zhang, J. (2025). Panax notoginseng improves the sensitivity of non-small cell lung cancer to cisplatin by inhibiting Akt signaling. Cancer Biomarkers. https://doi.org/10.1177/18758592241303377
Vancouver
Pan L, Zhang D, Shao Q, Cheng M, Liao Z, Yu L, et al. Panax notoginseng improves the sensitivity of non-small cell lung cancer to cisplatin by inhibiting Akt signaling. Cancer Biomarkers. 2025. doi:10.1177/18758592241303377
BibTeX
@article{Pan2025,
author = {Pan, Lizhen and Zhang, Dandan and Shao, Qiqi and Cheng, Maohao and Liao, Zhicheng and Yu, Lingpei and Wang, Yuanyuan and Jia, Pengcheng and Zhang, Jizhou},
title = {Panax notoginseng improves the sensitivity of non-small cell lung cancer to cisplatin by inhibiting Akt signaling},
journal = {Cancer Biomarkers},
year = {2025},
doi = {10.1177/18758592241303377}
}
EUVIMED